Giovanni Giorli1,2,3,4, Julie Rouette1,2, Hui Yin1, Francesco Lapi5, Monica Simonetti5, Claudio Cricelli5, Michael Pollak6,7, Laurent Azoulay1,2,7. 1. Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada. 2. Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada. 3. Department of Statistics and Quantitative Methods, Unit of Biostatistics and Epidemiology, University of Milano-Bicocca, Milan, Italy. 4. Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, UK. 5. Health Search, Italian College of General Practitioners and Primary Care - SIMG, Florence, Italy. 6. Segal Cancer Center, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada. 7. Gerald Bronfman Department of Oncology, McGill University, Montreal, Canada.
Abstract
AIMS: Previous studies suggest that the use of low-dose aspirin before a colorectal cancer (CRC) diagnosis may be associated with a decreased risk of CRC progression. Data supporting this association, however, have been inconsistent. We evaluate whether the use of prediagnostic low-dose aspirin is associated with a lower risk of metastases and all-cause mortality in CRC patients. METHODS: Using a large Italian population-based primary care database, we identified a cohort of 7478 patients newly diagnosed with nonmetastatic CRC between 2000 and 2013. Use of prediagnostic low-dose aspirin was compared with no use of low-dose aspirin. Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of incident metastasis and of all-cause mortality associated with prediagnostic low-dose aspirin use, both overall and by duration of use. RESULTS: There were 314 incident metastatic events and 2189 deaths during a mean follow-up time of 4.4 and 4.7 years, respectively. Overall prediagnostic use of low-dose aspirin was not associated with a decreased risk of incident metastasis (HR 0.88; 95% CI 0.63-1.22) or all-cause mortality (HR 1.09; 95% CI 0.96-1.22) in CRC patients. Cumulative duration of aspirin use was not associated with a decreased risk of incident metastasis (P-trend = .22) or all-cause mortality (P-trend = .38). These findings remained consistent in sensitivity analyses. CONCLUSION: In this real-world, population-based study, the prediagnostic use of low-dose aspirin was not associated with a decreased risk of incident metastasis or all-cause mortality in CRC patients.
AIMS: Previous studies suggest that the use of low-dose aspirin before a colorectal cancer (CRC) diagnosis may be associated with a decreased risk of CRC progression. Data supporting this association, however, have been inconsistent. We evaluate whether the use of prediagnostic low-dose aspirin is associated with a lower risk of metastases and all-cause mortality in CRCpatients. METHODS: Using a large Italian population-based primary care database, we identified a cohort of 7478 patients newly diagnosed with nonmetastatic CRC between 2000 and 2013. Use of prediagnostic low-dose aspirin was compared with no use of low-dose aspirin. Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of incident metastasis and of all-cause mortality associated with prediagnostic low-dose aspirin use, both overall and by duration of use. RESULTS: There were 314 incident metastatic events and 2189 deaths during a mean follow-up time of 4.4 and 4.7 years, respectively. Overall prediagnostic use of low-dose aspirin was not associated with a decreased risk of incident metastasis (HR 0.88; 95% CI 0.63-1.22) or all-cause mortality (HR 1.09; 95% CI 0.96-1.22) in CRCpatients. Cumulative duration of aspirin use was not associated with a decreased risk of incident metastasis (P-trend = .22) or all-cause mortality (P-trend = .38). These findings remained consistent in sensitivity analyses. CONCLUSION: In this real-world, population-based study, the prediagnostic use of low-dose aspirin was not associated with a decreased risk of incident metastasis or all-cause mortality in CRCpatients.
Authors: Farhat V N Din; Evropi Theodoratou; Susan M Farrington; Albert Tenesa; Rebecca A Barnetson; Roseanne Cetnarskyj; Lesley Stark; Mary E Porteous; Harry Campbell; Malcolm G Dunlop Journal: Gut Date: 2010-09-15 Impact factor: 23.059
Authors: Anna E Coghill; Amanda I Phipps; Anthony A Bavry; Jean Wactawski-Wende; Dorothy S Lane; Andrea LaCroix; Polly A Newcomb Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-08-29 Impact factor: 4.254
Authors: Claudio Cricelli; Giampiero Mazzaglia; Fabio Samani; Marco Marchi; Andrea Sabatini; Roberto Nardi; Giuseppe Ventriglia; Achille P Caputi Journal: J Public Health Med Date: 2003-09
Authors: Jason A Zell; Argyrios Ziogas; Leslie Bernstein; Christina A Clarke; Dennis Deapen; Joan A Largent; Susan L Neuhausen; Daniel O Stram; Giske Ursin; Hoda Anton-Culver Journal: Cancer Date: 2009-12-15 Impact factor: 6.860
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702